ES8502547A1 - Un metodo para determinar la presencia de una neoplasia. - Google Patents

Un metodo para determinar la presencia de una neoplasia.

Info

Publication number
ES8502547A1
ES8502547A1 ES522585A ES522585A ES8502547A1 ES 8502547 A1 ES8502547 A1 ES 8502547A1 ES 522585 A ES522585 A ES 522585A ES 522585 A ES522585 A ES 522585A ES 8502547 A1 ES8502547 A1 ES 8502547A1
Authority
ES
Spain
Prior art keywords
human
clnh11
clnh5
hybridom
neoplasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES522585A
Other languages
English (en)
Other versions
ES522585A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57084843A external-priority patent/JPS58201994A/ja
Priority claimed from US06/465,081 external-priority patent/US4618577A/en
Application filed by University of California filed Critical University of California
Publication of ES522585A0 publication Critical patent/ES522585A0/es
Publication of ES8502547A1 publication Critical patent/ES8502547A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METODO PARA DETERMINAR LA PRESENCIA DE UNA NEOPLASIA.CONSISTE EN COMBINAR, EN UN MEDIO DE ENSAYO ACUOSO TAMPONADO, CELULAS DE TEJIDO CERVICAL HUMANO SOSPECHOSAS DE SER NEOPLASICAS, COMO CARCINOMA CERVICAL, TUMOR DE PROSTATA, CANCER DE PULMON Y OTRAS, CON ANTICUERPOS MONOCLONALES CAPACES DE DISTINGUIR ENTRE CELULAS CERVICALES NORMALES Y NEOPLASICAS; ESTANDO MARCADOS LOS ANTICUERPOS CON UN MARCADOR CAPAZ DE PROPORCIONAR UNA SEN/AL DETECTABLE; Y DETECTAR LA UNION ENTRE LOS ANTICUERPOS Y LAS CELULAS DE TEJIDO HUMANO MEDIANTE LA OBSERVACION DE LA PRESENCIA DE SEN/AL EN EL MEDIO DE ENSAYO. LOS ANTICUERPOS MONOCLONALES SON OBTENIDOS DE UN HIBRIDOMA CLNH5 O CLNH11 HUMANO O DE HIBRIDOMAS DERIVADOS DE ESTOS
ES522585A 1982-05-21 1983-05-20 Un metodo para determinar la presencia de una neoplasia. Expired ES8502547A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
US06/465,081 US4618577A (en) 1983-02-09 1983-02-09 Human-human hybridoma, CLNH5

Publications (2)

Publication Number Publication Date
ES522585A0 ES522585A0 (es) 1985-01-01
ES8502547A1 true ES8502547A1 (es) 1985-01-01

Family

ID=26425823

Family Applications (2)

Application Number Title Priority Date Filing Date
ES522585A Expired ES8502547A1 (es) 1982-05-21 1983-05-20 Un metodo para determinar la presencia de una neoplasia.
ES528897A Expired ES8504463A1 (es) 1982-05-21 1984-01-16 Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES528897A Expired ES8504463A1 (es) 1982-05-21 1984-01-16 Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas

Country Status (7)

Country Link
US (3) US6051229A (es)
KR (1) KR880001567B1 (es)
CA (1) CA1247538A (es)
ES (2) ES8502547A1 (es)
IL (1) IL68752A (es)
IT (2) IT1203702B (es)
NZ (1) NZ204327A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5143566B2 (ja) 2004-12-21 2013-02-13 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド 癌特異的抗体および細胞表面タンパク質
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US9315403B1 (en) 2012-12-04 2016-04-19 Eldorado Biofuels, LLC System for algae-based treatment of water
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
JP6506267B2 (ja) 2013-10-03 2019-04-24 バイオケア メディカル， エルエルシー 抗ｓｏｘ１０抗体のシステムおよび方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
JPS57502090A (es) * 1980-07-18 1982-11-25
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line
US4594325A (en) * 1981-03-26 1986-06-10 The Regents Of The University Of Calif. High fusion frequency fusible lymphoblastoid cell line
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4434230A (en) * 1981-08-12 1984-02-28 Research Corporation Human nonsecretory plasmacytoid cell line
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4618585A (en) * 1982-03-18 1986-10-21 Board Of Regents, The University Of Texas System Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
US5286647A (en) * 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
JPS58201994A (ja) * 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列

Also Published As

Publication number Publication date
CA1247538A (en) 1988-12-28
ES522585A0 (es) 1985-01-01
US6051693A (en) 2000-04-18
IT8348350A0 (it) 1983-05-23
KR840004785A (ko) 1984-10-24
IL68752A (en) 1989-06-30
US6051387A (en) 2000-04-18
NZ204327A (en) 1986-03-14
ES528897A0 (es) 1985-04-16
IT1203702B (it) 1989-02-15
US6051229A (en) 2000-04-18
IT8321217A0 (it) 1983-05-20
KR880001567B1 (ko) 1988-08-22
ES8504463A1 (es) 1985-04-16

Similar Documents

Publication Publication Date Title
ZA833686B (en) Human human hybridomas for cervical carcinoma
IL67721A (en) Hybridoma cell lines,their preparation and their use for the production of human monoclonal antibodies
DE3687736T2 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
GB8800078D0 (en) Novel antibodies
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
MX9604391A (es) Anticuerpos monoclonales que reconocen el receptor de tie y su uso.
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
EP0210970A3 (en) Detection, imaging and therapy of renal cell carcinoma with monoclonal antibodies
MX9605895A (es) Anticuerpos monoclonales humanos especificos para antigeno de superficie de glioma independiente del ciclo celular.
ES8504463A1 (es) Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas
EP0232871A3 (en) Human monoclonal antibody, hybridoma producing the same and its use
EP0109434A4 (en) IN VITRO DIAGNOSTICS METHODS USING MONOCLONAL ANTIBODIES AGAINST PROTEINS OF CONNECTIVE TISSUES.
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
AR227907A1 (es) Un procedimiento para obtener relaxina humana,por cultivo"in vitro"de tejidos o celulas de decidua
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
PL323195A1 (en) Alpha unit of human integrin beta 2
IL75793A0 (en) Monoclonal antibodies against human ifn-ypsilon,their preparation and their use and hybrid cell lines producing these antibodies
EP0278160A3 (en) Human monoclonal anti cancer antibodies, hybridoma cell lines producing them and their uses
ZA878077B (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby
IL67944A0 (en) Antibodies and antigens useful in the diagnosis and treatment of cancer,methods for the production thereof and methods for testing for the presence of cancer cells using the same
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.